Abstract

Age-related macular degeneration (AMD) is the predominant cause of vision loss in the elderly with a major impact on ageing societies and healthcare systems. A major challenge in AMD management is the difficulty to determine the disease stage, the highly variable progression speed and the risk of conversion to advanced AMD, where irreversible functional loss occurs. In this study we developed an optical coherence tomography (OCT) imaging based spatio-temporal reference frame to characterize the morphologic progression of intermediate age-related macular degeneration (AMD) and to identify distinctive patterns of conversion to the advanced stages macular neovascularization (MNV) and macular atrophy (MA). We included 10,040 OCT volumes of 518 eyes with intermediate AMD acquired according to a standardized protocol in monthly intervals over two years. Two independent masked retina specialists determined the time of conversion to MNV or MA. All scans were aligned to a common reference frame by intra-patient and inter-patient registration. Automated segmentations of retinal layers and the choroid were computed and en-face maps were transformed into the common reference frame. Population maps were constructed in the subgroups converting to MNV (n=135), MA (n=50) and in non-progressors (n=333). Topographically resolved maps of changes were computed and tested for statistical significant differences. The development over time was analysed by a joint model accounting for longitudinal and right-censoring aspect. Significantly enhanced thinning of the outer nuclear layer (ONL) and retinal pigment epithelium (RPE)–photoreceptorinner segment/outer segment (PR-IS/OS) layers within the central 3 mm and a faster thinning speed preceding conversion was documented for MA progressors. Converters to MNV presented an accelerated thinning of the choroid and appearance changes in the choroid prior to MNV onset. The large-scale automated image analysis allowed us to distinctly assess the progression of morphologic changes in intermediate AMD based on conventional OCT imaging. Distinct topographic and temporal patterns allow to prospectively determine eyes with risk of progression and thereby greatly improving early detection, prevention and development of novel therapeutic strategies.

Highlights

  • Abbreviations AMD Age-related macular degeneration AO-optical coherence tomography (OCT) Adaptive optics OCT BM Bruch’s membrane directional OCT (D-OCT) Directional OCT DOM Difference of means false discovery rate (FDR) False discovery rate GCL Ganglion cell layer GLCM Gray-level co-occurence matrix

  • We focused on the onset of advanced AMD and assessed the spatio-temporal development distinguishing patients close to progression followed by conversion from patients that remained in an earlier stage of AMD

  • Patient population. 518 fellow eyes of 1,097 patients included in the HARBOR trial were diagnosed with intermediate AMD at baseline. 50 and 135 eyes developed macular atrophy (MA) or macular neovascularization (MNV) during the 24-month follow-up period, respectively. 333 eyes did not exhibit any significant progression to advanced AMD

Read more

Summary

Introduction

Abbreviations AMD Age-related macular degeneration AO-OCT Adaptive optics OCT BM Bruch’s membrane D-OCT Directional OCT DOM Difference of means FDR False discovery rate GCL Ganglion cell layer GLCM Gray-level co-occurence matrix. Establishing a common reference frame for OCT images is the initial step towards developing a spatio-temporal atlas detecting the characteristic pathomorphologic changes and the pathognomonic disease course in AMD. Such an atlas may provide a normative database of retinal ageing and age-related retinal pathology, allowing to compare the retinal configuration and progression speed of an individual to the general population - to normative databases widely available for the evaluation of retinal changes in g­ laucoma[8], but currently lacking for the much more frequent AMD disease.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call